JP Morgan Initiates Coverage On Viking Therapeutics with Overweight Rating, Announces Price Target of $80
Portfolio Pulse from Benzinga Newsdesk
JP Morgan has initiated coverage on Viking Therapeutics with an Overweight rating and set a price target of $80.
September 11, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has initiated coverage on Viking Therapeutics with an Overweight rating and a price target of $80, indicating a positive outlook.
The initiation of coverage by a major financial institution like JP Morgan with an Overweight rating and a high price target suggests confidence in Viking Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in VKTX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100